CKD CHCRT
CKD CHCRT
CKD CHCRT
Definition of CKD
Structural or functional abnormalities of
the kidneys for >3 months, as
manifested by either:
1. Kidney damage, with or without decreased
GFR, as defined by
pathologic abnormalities
markers of kidney damage, including
abnormalities in the composition of the blood or
urine or abnormalities in imaging tests
Dialysis
10
General population
1
0.1
Male
Female
0.01
Black
White
2534 3544 4554 5564 6574 7584
Age (years)
85
STAGES
K/DOQI GUIDELINES
STAGES OF CKD
Normal
Normal
Screening
for CKD
risk factors
Increased
Increased
risk
risk
CKD risk
reduction;
Screening for
CKD
Damage
Damage
GFR
GFR
Kidney
Kidney
failure
failure
Diagnosis
Estimate
Replacement
& treatment; progression;
by dialysis
Treat
Treat
& transplant
comorbid complications;
conditions;
Prepare for
Slow
replacement
progression
CKD
CKD
death
death
700
600
Glomerulonephritis
13%
Hypertension
27%
Diabetes
50.1%
No of Patients
Projection
95% CI
500
Number of
400
Dialysis
Patients
300
200
100
0
520,240
281,355
243,524
R2 = 99.8%
1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010
ETIOLOGY
Etiology
glomerulonephritis
Obstruction
Diabetic nephropaty
Lupus nephritis
Polycystic KD
Hypertension
Unknown
Centre nephrology in Indonesia
Sidabutar RP ( 1989 ) *
1989 *
1996
40,12%
36,7%
6,13%
4,17%
2,12%
2,09%
9,32%
46,19%
12,85%
18,65%
0,16%
1,41%
8,46%
15,2%
2000
39,64%
13,44%
17,54%
0,23%
2,51%
15,72%
10,93%
(140 Umur) X BB
Klirens Keatinin (ml/men.) = ---------------------------------- X (0.85 jika
wanita)
72 X Kreatinin serum
Penatalaksanaan CKD
Ditujukan untuk mengurangi gejala klinik , mencegah komplikasi ,
mencegah progresifitas CKD, mempersiapkan initiasi dialisis
Uremia
: diit protein 0,8 0,6 gr / kg bb / hari
Hiperkalemia
: diit rendah kalium ; 60 80 meq/hari
Asidosis metabolik : diit rendah protein / fosfat; HCO3
Stop rokok
Kontrol lipid ( preparat statin )
HbA1C < 7 %
Hipertensi
Anemia
Osteodistrofi renal
Komplikasi kardiovaskuler
Microalbuminuria
(only abnormality)
Proteinuria
Diabetes Mellitus
130/80
130/80
ACE Inhibitor
(or ARB)
Start
And
Titrate
To maximum
Tolerable
Dose
hypertension
K/DOQI, 2004 / ADA, 2003 / JNC 7, 2003 : Target BP 130/80 mmHg
Lifestyle modification : DASH diet, exercise, etc
Agent is ARB, ACE-inh (initial) : Hypertension Diabetic Kidney Disease and
Nondiabetic Kidney Disease
BP >130/80 mmHg
BP <130/80 mmHg
BP < 125 / 75 mmHg
Target BP
<130/80 mmHg
Anemia
Target hematocrit pre-dialysis , hemodialysis
Relieve symptom,
- erithropoetin
- preparat - iron ( bila kadar serum iron kurang )
Blood Pressure
Target
(mm Hg)
Preferred Agents
for CKD, with or
without
Hypertension
Other Agents
to Reduce CVD Risk
and Reach Blood
Pressure Target
ACE inhibitor
or ARB
Diuretic preferred,
then BB or CCB
<130/80
None preferred
Diuretic preferred,
then ACE inhibitor,
ARB, BB or CCB
CCB, diuretic, BB,
ACE inhibitor, ARB
At
increased
risk
Kidney Damage
and normal
or GFR
Stage 1
Kidney Damage
and mild
GFR
Stage 2
90
60
Moderate
GFR
Severe
GFR
Kidney Failure
Stage 3
Stage 4
Stage 5
30
15
GFR
Primary care
physician
Nephrologist
Indikasi Dialisis
GFR < 10 ( < 15 pada DM )
Sindroma uremikum
Overhidrasi
Asidosis Metabolik
Hiperkalemia
Infeksi
Others Choices
CAPD
Transplantation
Keuntungan
HD
Sangat efisien
Mendpt follow-up medis
Protein loss lewat dialisis ( - )
Kerugian
Risiko tinggi pd Pendrt Ggn
kardiovaskuler berat
Sering memerlukan perbaikan
AV fistula iskemik pd tangan
Sering terjadi episode
hipoglikemik & hipotensi
Hiperkalemi
Membran biokompatibel X darah sitokin
inflamasi progresifitas
Heparin perdarahan retina
CAPD
Toleransi kardiovaskuler
Tanpa AV fistula
Kalium serum terkontrol
Kadar gula terkontrol insulin
intraperitoneal
Hipoglikemi jarang terjadi
SUMMARY
The
TERIMA KASIH